Orphalan has launched the global Phase 3 TRADITiONAL study comparing an investigational once-daily trientine tetrahydrochloride formulation with D-penicillamine over 48 weeks.
Immutep finds manufacturing differences after TACTI-004 and refocuses efti on head and neck cancer and sarcoma. See what comes next.
LUMA Vision has secured additional FDA clearance for VERAFEYE, integrating real-time 2D and 3D cardiac anatomy, catheter tracking and procedural guidance ahead of a planned 2027 U.S. launch.
The FDA has cleared Alebund Pharmaceuticals’ AP308 IND, allowing a first-in-human study of an engineered IgA protease designed to remove pathogenic IgA and immune complexes in IgA nephropathy.
Amgen’s Phase 3 DeLLphi-305 trial met its primary overall survival endpoint with Imdelltra plus Imfinzi as first-line maintenance in extensive-stage small cell lung cancer.
The FDA has accepted Nanoscope Therapeutics’ BLA for MOGENRY, an optogenetic therapy designed to restore useful vision in severe retinitis pigmentosa regardless of the underlying mutation.
Cleveland Clinic has completed the first human implantation of Corcym’s TriMemo annuloplasty ring, moving a purpose-built Nitinol platform into tricuspid repair as cardiac surgery faces growing competition from transcatheter structural-heart therapies.
Abbott’s TactiFlex Duo combines pulsed field ablation and radiofrequency energy in one contact-force catheter, giving electrophysiologists a way to move between tissue-selective PFA and conventional thermal ablation without changing platforms during an AFib procedure.
Arlocabtagene autoleucel met response and complete-response endpoints in patients already exposed to immunomodulators, proteasome inhibitors, anti-CD38 treatment and BCMA therapy, positioning GPRC5D as a possible next CAR T target after increasingly crowded myeloma treatment sequences.
Once-daily deucrictibant XR reduced hereditary angioedema attacks by 83% across the Phase 3 CHAPTER-3 population, giving Pharvaris a potential oral prophylaxis product alongside its separately developed immediate-release rescue formulation.